

Guidance Document

Location of Delivery of Systemic Anti-Cancer Therapy (SACT)

Within the Kent and Medway Cancer Collaborative

Status	Final
Expiry Date	May 2019
Version Number	V4
Publication Date	April 2018

Contents

Contents		
LOCATION OF DELIVERY OF SYSTEMIC ANTI-CANCER THERAPY (SACT) WITHIN THE KENT AND MEDWAY CANCER COLLABORATIVE		3
1.0	<i>Maidstone and Tunbridge Wells NHS Trust</i>	3
1.1	Maidstone General Hospital – Kent Oncology Centre	3
1.2	The Tunbridge Wells Hospital at Pembury	3
2.0	<i>Dartford and Gravesham NHS Trust</i> – Darent Valley Hospital	4
3.0	<i>Medway NHS Foundation Trust</i> – Medway Maritime Hospital	4
4.0	<i>East Kent University Hospitals NHS Foundation Trust</i>	4-5
4.1	Queen Elizabeth The Queen Mother Hospital	4
4.2	William Harvey Hospital	5
4.3	Kent and Canterbury Hospital	5
	Document Administration	6
	Enquiries	6
	Document Location	6
	Revision History	7

LOCATION OF DELIVERY OF SYSTEMIC ANTI-CANCER THERAPY (SACT) WITHIN THE KENT AND MEDWAY CANCER COLLABORATIVE

The term “systemic anti-cancer therapy” is generally used to refer to any agent that may be genotoxic, oncogenic, mutagenic or teratogenic. This agent will be absorbed into the body and be able to be distributed throughout it via bio-chemical pathways.

For the purpose of this document, drugs which are considered to be systemic are listed in the most recent version of the British National Formulary (BNF) Pharmaceutical Press, Section 8.1. Drugs affecting the immune response, antiproliferative immunosuppressants are listed in Section 8.2 of the BNF. If in doubt, refer to the summary of Medical Product Characteristics available at www.medicines.org.uk for the individual drug concerned.

Systemic anti-cancer therapy antibodies will also be subject to the guidance within this document.

1.0 MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST

1.1 *Maidstone General Hospital – Kent Oncology Centre*

- All systemic anti-cancer therapy can be delivered on the Charles Dickens Day Unit with the exception of intrathecal, ocular, intravesical, intraperitoneal, intrapleural and high dose methotrexate.
- The Chartwell Suite is a separate entity for private patients and can deliver all systemic anti-cancer therapy with the exception of intrathecal, ocular, intravesical, intraperitoneal, intrapleural and high dose methotrexate.
- Lord North Ward can deliver all systemic anti-cancer therapy and specialise in haematology regimes. High dose methotrexate is only given on Lord North Ward.
- In addition to this Riverside is able to administer vinca-alkaloids for paediatric systemic anti-cancer therapy.
- There is a designated room on Lord North Ward for administration of Intrathecal chemotherapy.

1.2 *The Tunbridge Wells Hospital at Pembury*

- All systemic anti-cancer therapy can be delivered on the Haematology-Oncology Day Unit with the exception of intrathecal, ocular, intravesical, intraperitoneal, intrapleural and high dose methotrexate.
- No Intrathecal chemotherapy is delivered at this site.

2.0 DARTFORD AND GRAVESHAM NHS TRUST – Darent Valley Hospital

- The Pine Therapy Unit and Rosewood Ward are designated to deliver all systemic anti-cancer therapy with the exception of intrathecal, ocular, intraperitoneal and intrapleural.
- Systematic anti-cancer therapy is also given when necessary on ITU and Laural ward which is a High Dependency Ward. Redwood ward is also a designated area as Bortezomib is given to Myeloma patients that are attending Redwood for dialysis.
- Intravesical systemic anti-cancer therapy is administered either in The Day Care Unit or on Cherry Ward.
- In addition no paediatric systemic anti-cancer therapy is delivered within this Trust.

3.0 MEDWAY NHS FOUNDATION TRUST – Medway Maritime Hospital

- All haemato-oncology outpatient systemic anti-cancer therapy with the exception of intravesical therapy is delivered at the Medway Macmillan Chemotherapy Unit which comprises the Galton Day Unit and Lawrence Ward.
- Lawrence Ward can deliver all systemic anti-cancer therapy and specialise in haematology regimes. High dose methotrexate is only given on Lawrence Ward.
- Haematology patients are not treated separately unless there is a clinical need to deliver a regimen as an inpatient. There are identified side rooms on Galton Day Unit to accommodate these patients.
- In addition, there is a dedicated room on Lawrence Ward solely for the administration of intrathecal anti-cancer therapy.
- Intravesical anti-cancer therapy is exclusively administered in Outpatients area 3 and day surgery.

4.0 EAST KENT HOSPITALS UNIVERSITY FOUNDATION TRUST

Please note intrathecal chemotherapy is not administered on any of the site within the East Kent Hospitals University Foundation Trust

4.1 Queen Elizabeth The Queen Mother Hospital

- All systemic anti-cancer therapy excluding intrathecal, ocular, intravesical, intraperitoneal or intrapleural is delivered at Viking Day Unit
- No chemoradiotherapy, BEP regime, twice-daily Cytarabine or in-patient haematological anti-cancer therapy is delivered at this site.

4.2 William Harvey Hospital

- All systemic anti-cancer therapy except intrathecal, ocular, intravesical, intraperitoneal or intrapleural is delivered at the Celia Blakey Centre.
- No chemo radiotherapy, BEP regime for urological and gynaecological cancers, twice-daily Cytarabine or in-patient haematological anti-cancer therapy is delivered at this site.

4.3 Kent and Canterbury Hospital

- All systemic anti-cancer therapy except ocular, intravesical, intraperitoneal or intrapleural is delivered at the Cathedral Day Unit.
- Inpatient haematological anti-cancer therapy is delivered on Brabourne Ward.

This trust offers a mobile chemotherapy service.

Please refer to local policies as to what can be treated within this unit.

5.0 Routinely teenager and young adults requiring SACT are referred to the appropriate tertiary centre.

5.1 Teenagers and young adults if required will be treated in the areas designated for adult SACT administration

6.0 For SACT administration in Intensive Care Units (ITU) please refer to the SACT health and safety and administration policy.

Document Administration

Approval Record

Approval		
Date	Name / Title	Signature
07/05/2009	Circulated for comments and feedback to Network Chemotherapy Group Network Nursing and Pharmacy Group and local Trust Chemotherapy Groups	
21/05/2009	Ratified at Network Nursing and Pharmacy Group	
16/09/2010	Sarah Wade – KMCN Pharmacy Technician Linda Caine – KMCN SIF Update current information based on CYP OP and new facilities in Medway	
February 2011	Ratified by the Network Chemotherapy Group	

Enquiries:

All enquiries relating to this document should be addressed to:

Addressee: Name Caroline Waters
 Collaborative Pharmacist and Clinical Lead
 Arundel Unit, William Harvey Hospital,
 Kennington Road,
 Ashford, Kent,
 TN24 0LZ

Address Kent and Medway Cancer Collaborative,

Email: caroline.waters2@nhs.net

Document Location

The document is located in the Kent and Medway Cancer Collaborative office, in hardcopy and in electronic format on the Kent & Medway Cancer Collaborative website at www.kmcc.nhs.uk

Date of Next Review

This item is next to be reviewed in **June 2019** by the Lead Chemotherapy Nurses across the Collaborative

Revision History

Date	Version	Status	Author	Summary of Changes
11/05/2009	V0.5	Draft	Sarah Wade	Addition of Kent and Sussex HODU
28/05/2009	V0.6	Draft	Bryony Neame	Wording changes as suggested by Kent Oncology Centre chemotherapy staff. No operational changes.
02/06/2009	V0.7	Draft	Sarah Wade	Wording changes as suggested by M Plant – Lead Haematology Pharmacist EKHT. No operational changes.
24/06/2009	V0.8	Draft	Sarah Wade	Grammar changes and clarification of treatments given at Maidstone Hospital. No operational changes
August 10	V1.1	Draft	Sarah Wade	Updated to reflect changes in both practice and naming of location of delivery.
February 11	V2	Final	Sarah Wade	Published
March 17	V3	Final	C. Wade C. Maynard C. Hardy T. Rigden	Updated to reflect changes within trusts.
April 2018	V3.1	Draft	P.Williams C.Wadey	Section 4.3. BEP information updated to reflect use at Kent and Canterbury Hospital.
April 2018	V4	Final	C.Wadey	Published